Objective: Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reducing the incidence of exacerbations in these patients. Methods: Patients treated with Trypsone® or Prolastin® for at least 18 months were recruited if their medical records for 18 months before starting augmentation therapy were available. The number of mild and severe exacerbations in the two periods was compared and hospitalization-related costs were analysed. Results: A total of 127 patients were recruited; 75 of them experi...
Abstract Alpha-1 antitrypsin deficiency (AATD) is a common hereditary disorder caused by mutations i...
Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstruc...
Adriana-Maria Hiller,1 Eeva Piitulainen,1 Lars Jehpsson,2 Hanan Tanash11Department of Respiratory Me...
SummaryBackgroundThe frequency, characteristics and impact of acute exacerbations in patients with a...
Patients with inherited alpha-1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructiv...
Rationale: Alpha-1 antitrypsin deficiency (AATD) is characterized by decreased circulating levels or...
BACKGROUND Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition predisposing individ...
Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pul...
Alpha-1 antitrypsin (AAT) deficiency is a hereditary condition characterized by low levels of AAT in...
BACKGROUND: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. MET...
Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Ad...
OBJECTIVE: To prepare new guidelines for the Canadian Thoracic Society (CTS) regarding severe alpha1...
Background: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is t...
Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. Met...
Study objectives: To propose an hypothesis that antiprotease augmentation therapy reduces the incide...
Abstract Alpha-1 antitrypsin deficiency (AATD) is a common hereditary disorder caused by mutations i...
Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstruc...
Adriana-Maria Hiller,1 Eeva Piitulainen,1 Lars Jehpsson,2 Hanan Tanash11Department of Respiratory Me...
SummaryBackgroundThe frequency, characteristics and impact of acute exacerbations in patients with a...
Patients with inherited alpha-1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructiv...
Rationale: Alpha-1 antitrypsin deficiency (AATD) is characterized by decreased circulating levels or...
BACKGROUND Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition predisposing individ...
Patients with inherited α1-antitrypsin (AAT) deficiency (ZZ-AATD) and severe chronic obstructive pul...
Alpha-1 antitrypsin (AAT) deficiency is a hereditary condition characterized by low levels of AAT in...
BACKGROUND: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. MET...
Intravenous infusion of alpha-1 antitrypsin (AAT) was approved by the United States Food and Drug Ad...
OBJECTIVE: To prepare new guidelines for the Canadian Thoracic Society (CTS) regarding severe alpha1...
Background: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is t...
Background: Alpha-1-Antitrypsin Deficiency (AATD) is an economically unexplored genetic disease. Met...
Study objectives: To propose an hypothesis that antiprotease augmentation therapy reduces the incide...
Abstract Alpha-1 antitrypsin deficiency (AATD) is a common hereditary disorder caused by mutations i...
Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstruc...
Adriana-Maria Hiller,1 Eeva Piitulainen,1 Lars Jehpsson,2 Hanan Tanash11Department of Respiratory Me...